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Abstract
Background:  A new priority in genome research is large-scale resequencing of genes to
understand the molecular basis of hereditary disease and cancer. We assessed the ability of
massively parallel pyrosequencing to identify sequence variants in pools. From a large collection of
human PCR samples we selected 343 PCR products belonging to 16 disease genes and including a
large spectrum of sequence variations previously identified by Sanger sequencing. The sequence
variants included SNPs and small deletions and insertions (up to 44 bp), in homozygous or
heterozygous state.
Results: The DNA was combined in 4 pools containing from 27 to 164 amplicons and from 8,9 to
50,8 Kb to sequence for a total of 110 Kb. Pyrosequencing generated over 80 million base pairs of
data. Blind searching for sequence variations with a specifically designed bioinformatics procedure
identified 465 putative sequence variants, including 412 true variants, 53 false positives (in or
adjacent to homopolymeric tracts), no false negatives. All known variants in positions covered with
at least 30× depth were correctly recognized.
Conclusion: Massively parallel pyrosequencing may be used to simplify and speed the search for
DNA variations in PCR products. Our results encourage further studies to evaluate molecular
diagnostics applications.
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Background
The availability of a reference human DNA sequence and
high throughput technologies such as automated DNA
sequencing has made the identification of sequence varia-
tions a key tool in several fields of modern biology. Rese-
quencing of large sets of clinically relevant genes, in order
to identify variants, is important for understanding the
molecular basis of disease and, consequently, for develop-
ing diagnostic tests and identifying drug targets. Thus far,
large resequencing projects have used a standard sequenc-
ing procedure in which gene fragments are amplified by
PCR, purified and subjected individually to Sanger
sequencing on both strands [1,2].
New-generation genome sequencing technologies have
the potential to simplify this task. These new technologies
are based on sequencing-by-hybridization [3], sequenc-
ing-by-ligation [4] or sequencing-by-synthesis [5,6]. The
latter methodology, sequencing-by-synthesis, is imple-
mented in the Genome Sequencer GS-FLX System (454
Life Sciences), which produces several hundred thousand
DNA reads of at least 200 bp; this is done by monitoring
the release of pyrophosphate during the growth of a DNA
chain driven by a DNA polymerase [6]. The very high
throughput of the instrument is achieved by massively
parallel pyrosequencing reactions, which generate a
highly redundant representation of the DNA regions
under scrutiny.
The GS-FLX has been already employed in bacterial
genome sequencing, miRNA discovery, cDNA sequenc-
ing, ultra-deep sequencing of PCR amplicons and in other
fields of application http://www.454.com/news-events/
publications.asp. In a few papers, the technology has been
used to generate detailed pictures of large genomic regions
by either multiplexed PCR approaches [7,8] or direct
genomic enrichment [9,10]. None of these studies, how-
ever, included a thorough analysis for known sequence
variants. Therefore, in this study, we assessed the perform-
ance of massively parallel pyrosequencing in the blind,
automated search for sequence variations within pools of
PCR-amplified DNA from clinical samples.
Results
We evaluated the performance of the new pyrosequencing
technology of the GS-FLX (454 Life Sciences – Roche) in
identifying sequence variants in pools of amplicons from
human genomic DNA. We selected 16 genes associated
with human genetic diseases (Table 1). Genes ranged in
size from 4 to 50 exons and had marked allelic heteroge-
neity. We obtained PCR-amplified DNA corresponding to
these genes from the DNA inventory of San Raffaele Hos-
pital; all DNA samples had previously been sequenced by
standard Sanger technique. Overall, 165 amplicons, con-
taining 374 genetic variants, were obtained. These ampli-
cons were mixed into four unequal pools (Supplementary
Table 1 [see Additional file 2]) to test the ability of the
sequencer to handle more or less complex DNA mixtures.
Several amplicons were included in more than one pool,
but always from different patients (not necessarily with
the same sequences); therefore, we analyzed a total of 343
PCR products harboring 429 variants previously con-
firmed by Sanger sequencing: 350 heterozygous SNPs, 43
homozygous SNPs, 23 deletions from 1 to 44 bp (all but
one in heterozygous state), and 13 heterozygous inser-
tions from 1 to 7 bp.
Amplicon pools were sequenced following the standard
GS-FLX procedure. The large set of reads generated was
aligned to the reference genomic sequences, yielding a
highly redundant representation of the target regions.
Sequence variations were detected in blind, without
knowledge of the previously determined genotypes.
Amplicon pools and sequence coverage
The four pools contained from 27 to 164 of the 343 PCR
products (Table 2 [see Additional file 1]). In each pool,
equimolar amounts of each PCR product were used.
Amplicons ranged from 121 to 569 bp (mean, 315 bp).
The reference genome complexity ranged from nearly 9
Kb (pool 4) to over 50 Kb (pool 1), for a total of nearly
110 Kb to be resequenced. Sequencing with the GS-FLX
generated over 373 000 reads for over 80.8 Mb of
sequence. Blast mapping collected nearly 60 Mb (73%) of
matched sequences; the remaining 27% was artifactual,
mainly primer dimers, presumably generated during the
original amplification reactions in which the amplicons
were made. Mean read length was 222 bp, well within GS-
FLX specifications. Pool 4 (the smallest) had a lower aver-
age read length (198 bp), possibly due to the over-repre-
sentation of short amplicons. Overall, 104 700 bases
(95,6%) of the reference sequence was covered at least
30× depth, considered the minimum necessary for relia-
ble sequence variation detection based on preliminary
experiments; 309 of the 343 amplicons were fully covered
above this threshold. At a less restrictive 10× depth of cov-
erage, 319 amplicons were fully covered (98,0% of bases).
Identification of sequence variations
The redundant representation of input sequences was
used to calculate the percentage base calls for every
sequence position covered ≥ 30×. For positions with
sequence heterogeneity, we considered only those in
which the minor allele had an allelic fraction > 20%.
Thus, 506 sequence variants were identified, with the
smallest pool presenting 48 variants and the largest 221
variants (Table 3 [see Additional file 1]). The variants were
classified, on the basis of the sequencing results from for-
ward and reverse reads, into top confident (TC), very con-
fident (VC) or not confident (NC) classes. Altogether, 41BMC Genomics 2008, 9:464 http://www.biomedcentral.com/1471-2164/9/464
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variants were classified as NC and not further considered
(none corresponded to sequence variations defined by
Sanger sequencing). There were 379 TC calls, of which
357 (94,2%) were found to correspond to the known
sequences once the data were unblinded; There were also
86 VC calls, of which 55 (64,0%) were correctly called.
Thus, there were altogether 53 miscalls (TC and VC), giv-
ing a false-positive rate of 0,05% for the total 104 700
bases covered ≥ 30×. Considering the 393 SNP variations,
the percentage agreement was 98,5% for TC calls (Supple-
mentary Table 2 [see Additional file 2]). In contrast, for
Table 1: Reference information for 16 genes (165 amplicons, representing 374 different sequence variants) included in the study
Gene OMIM Reference sequence Reference Amplicons, n Nucleotide variations, n
ABCA3 610921 NCBI-NM_001089 14 15 22
ABCA4 248200 NCBI-U88667 15 51 115
604116
601718
153800
CACNA1A 141500 ENSG00000141837 16 26 39
108500
183086
CFTR 219700 ENSG00000001626 17 13 22
277180
EGR2 607678 ENSG00000122877 * 4 6
FTH 134770 NCBI-NM_002032 18 5 10
FTL 600886 NCBI-NM_000146.3 19 5 12
GJB1 302800 ENSG00000169562 * 5 13
HBB 604131 NCBI-NT_009237 20 2 11
IRP2 147582 NCBI-NT_010194 * 5 16
LAMIN A/C 181350 ENSG00000160789 21 10 36
159001
605588
115200
151660
248370
176670
MPZ 118200 ENSG00000158887 * 5 14
PMP22 162500 ENSG00000109099 * 4 7
118300
SFTPB 267450 NCBI-M24461 14 4 10
265120
SFTPC 267450 NCBI-J03890 14 3 13
610913
SLC40A1 606069 NM_014585 23 8 28
* PCR primers and conditions available on requestBMC Genomics 2008, 9:464 http://www.biomedcentral.com/1471-2164/9/464
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the 36 insertions and deletions, only 56,4% of TC and
28,6% of VC calls agreed with known sequences.
We also assessed the ability of the GS-FLX to identify the
429 sequence variations known by Sanger sequencing.
Overall, 17 variants were missed: 15 heterozygous SNPs,
1 deletion and 1 insertion (Table 3 [see Additional file 1]).
These 17 variants had all been covered at less than 30×
depth, our cutoff for inclusion in the analysis. Had the
coverage threshold been 10×, we would have identified
seven of these missed variations, but we would have also
included seven more miscalls, increasing the number of
false positives (Supplementary Table 3 [see Additional file
2]).
In this study, we used a 30× sequence coverage as the min-
imum necessary for accurate calling with the GS-FLX.
Actual coverage with this instrument exceeded 4000× in a
few cases, and nearly 10% of the total 110 Kb sequence
had an average coverage depth above 1000×. To under-
stand the importance of coverage depth on the accuracy of
the sequence calls, we plotted coverage vs. allelic fraction
of the heterozygous variants identified in pool 1 (Figure
1). This analysis showed decreasing variability in allelic
fraction with increasing coverage; as coverage increased,
the values approached 0.5, the theoretical allelic fraction
for one allele of a biallelic polymorphism.
Impact of homopolymers and large indels
The 53 false positives (40 deletions, 7 insertions, and 6
heterozygous SNPs) obtained with pyrosequencing were
checked by repeat Sanger sequencing, which in all cases
confirmed the GS-FLX error. These miscalls were all
observed to lie in homopolymers, i.e. stretches of at least
three consecutive repeats of the same nucleotide. To
understand the role of homopolymers in generating false-
positive miscalls with the GS-FLX, we determined the
presence of this sequence pattern in the 110 Kb DNA
under scrutiny (Table 4 [see Additional file 1]. We identi-
fied 6840 homopolymers from 3 to 9 bp in length, for a
total of over 23 Kb (21% of the DNA sequenced). Thus,
only a very small fraction of homopolymers (53 of 6840;
0,78%) was associated with a miscall. However, the prob-
ability of a miscall increased with the length of the
homopolymer; in particular the 108 homopolymers of 6
or more bp (1.6% of total) were associated with 26
Relationship between sequence coverage with the GS-FLX and allelic fraction of heterozygous variations in pool 1 Figure 1
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(48,1%) of the 53 miscalls. In contrast, homopolymers
were not associated with any false-negative calls: consid-
ering sequence positions covered ≥ 30×, a total of 132
sequence variants known by Sanger sequencing were con-
tained within homopolymers (Supplementary Table 4
[see Additional file 2]). All were correctly identified.
Finally, since the Blast mapping procedure used in the
study was found, in preliminary work, to fail on deletions
or insertion longer than 10 bp, we devised a separate Blast
procedure to analyze GS-FLX reads for these variants. This
procedure found no large insertion but, in pool 4, one 44-
bp heterozygous deletion in exon 49 of Abca4. These find-
ings agree with the variants known by Sanger sequencing.
Discussion
We assessed the potential of massively parallel pyrose-
quencing to identify sequence variants in pools of ampli-
cons. Sequencing specificity at reasonable coverage depth
(30×) was better than expected, with only 0,05% false-
positive calls. Furthermore, the specificity of detection of
SNPs was excellent (98,5% for TC calls) whereas errors
were mostly related to indels, all lying within homopoly-
mers. False negatives, of primary relevance in diagnostic
applications, were absent, provided that 30× coverage
depth was attained.
In order to widen the applicability of our approach, we
purposely avoided any primer redesign or primer resyn-
thesis (including primer tails for 454 sequencing as
required by the GS-FLX protocol for amplicon sequenc-
ing). Tailed oligomers can help in sequencing an ampli-
con on one side. If both sides are to be sequenced (for
increasing reliability and for covering amplicons larger
than 250 bp as in this study) one should purchase two
new primer couples and run two separate amplifications
for each amplicon in the pool. In contrast, library prepa-
ration following the conventional 454 sequencing
approach (Supplementary Figure 1) yields the required
material with little additional time compared to the dou-
bling of amplicon preparation and processing. Indeed,
this approach could be of interest to all those who rou-
tinely identify sequence variations using any PCR-based
technique.
The sample material in this study consisted of amplicons
that varied greatly in length, sequence composition and
sequence variations. Several of these amplicons were from
the same genomic region amplified under the same con-
ditions from different patients, with and without such
mutations. We chose this experimental design in order to
explore the performance of this approach depending on
the molecular complexity under investigation. The pooled
DNA samples were subjected to 454 sequencing and the
resulting highly redundant representation of the targeted
regions was used for blind, bioinformatics identification
of sequence variants.
We attempted to normalize the concentrations of ampli-
cons in the pools in order to minimize the variability in
the coverage depth among different DNA fragments.
However, despite accurate measurements of concentra-
tions before pooling, there was substantial variability in
the depth of coverage. Nonetheless, a very high average
coverage was attained (400×). A relevant fraction of
sequence positions (4%, corresponding to nearly 5 of 110
Kb) was below 30× coverage, thus preventing a reliable
call according to our predefined parameters. With less
stringent 10× coverage, 2 Kb was still below the threshold.
On the other hand, nearly 10% of the sequence had an
average coverage depth above 1000×, peaking at over
4000× in a few cases. These areas of great coverage "waste"
a considerable proportion of sequencing power, making
this approach less productive than expected and requiring
the collection of many more reads than the minimum
necessary to exhaustively cover the entire region under
scrutiny.
The variability in amplicon coverage may depend on
length and GC content, which affect amplification effi-
ciency in emulsion PCR [4]. Alternatively, it may depend
on ligation efficiency, which is affected by the sequence of
the 3' and 5' ends [11]. We found no clear relationship
between coverage and either amplicon length or GC con-
tent. However, similar problems have been observed in a
large resequencing project using the Sanger method,
despite the possibility of PCR and sequencing optimiza-
tion [1]. In a defined diagnostic setting, notwithstanding
the reason for such biased (variable) coverage, this prob-
lem could be solved by increasing the quantity of "low-
yield" amplicons with respect to that of "high yield" ones
[7]. After a few trials, normalization conditions could be
defined and used for every new sample.
Definition of parameters and identification of sequence 
variations
Sequence variations were searched for by comparing
actual base calls to the expected sequence known from
Sanger sequencing. In preliminary experiments, we evalu-
ated data with 10× and 30× coverage depth, and observed
that 10× coverage did not guarantee an allelic fraction
(representation of the two alleles) of at least 20%. There-
fore, we set our coverage threshold to 30×. To further
improve the confidence of the sequencing results, we
devised a classification system based on empirical obser-
vations. When both strands called the same variation, the
call was classified as "top confident" (TC) call; consider-
ing only SNPs, only 5 of 340 TC calls were not confirmed;
these miscalls were within homopolymers. When just one
strand was available for sequence recognition (typically inBMC Genomics 2008, 9:464 http://www.biomedcentral.com/1471-2164/9/464
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amplicons longer that 250 bases when the variation was
close to the amplicon's ends), the variation was classified
as "very confident" (VC); only 1 of 44 VC SNP variants
was a miscall, again lying within a homopolymer. When
there were conflicting results between forward and reverse
strands, we gave a "not confident" (NC) classification; this
was the case in only 41 base positions. None of these NC
calls corresponded to a true variation. Such miscalls were
found in amplicons longer than 250 bp and were due to a
decrease of sequence quality at the end of the read on one
strand. Although this does not seem to be a general prob-
lem, when these miscalls occur, they can be simply dis-
carded based on automated classification and visual
inspection.
Pyrosequencing is known to be affected by over- or under-
calling within homopolymers [12]. Although the com-
bined length of homopolymers totaled nearly 23 Kb, we
had just 53 false-positive calls (forty 1-bp deletions, seven
1-bp insertions, and six SNPs) lying within these regions.
The miscall rate increased with homopolymer length, up
to 9 bp in this study. In continuing experimentation, we
have preliminary observations that, in longer homopoly-
mers (e.g. 15- to 20-mers), the length of false-positive
deletions also increases beyond single base pairs (unpub-
lished observations). However, since the GS-FLX correctly
called 132 sequence variations within homopolymers,
these regions should not always be considered unreliable.
Nonetheless, deletions and insertions in long homopoly-
mers should be carefully evaluated.
Considering the four pools separately, no clear indication
of a specific bias for accuracy was found. However, the
smallest pool had the poorest performance in terms of
mean coverage.
Evaluation of diagnostic applicability
False positives (overcalling of variations) were reasonably
low: we demonstrated an overall 99,95% specificity in
base calling (53 miscalls within 104.7 Kb of sequence cov-
ered ≥ 30×). All these miscalls were in homopolymeric
sequences and more frequently involved deletions and
insertions (n = 47) rather than SNPs (n = 6).
False negatives are a major issue in diagnostics applica-
tions. In this study, they were absent among amplicons at
≥ 30× coverage (100% sensitivity). However, 17 of 429
known sequence variations (4,0%) were missed due to
insufficient coverage. Decreasing the minimum coverage
to 10× led to the identification of 7 additional variants.
Nevertheless, with such a low coverage 7 additional mis-
calls were added, thus lowering specificity. In addition, a
decrease in coverage depth was associated with a greater
variability in allelic fraction, making it difficult to reliably
call heterozygous variations. Indeed, high redundancy
represents one of the major advantages of this approach,
allowing for a detailed molecular description of complex
mixtures of nucleic acids [13]. Therefore, according to our
experience, a minimum 30× coverage depth is required
for reliable detection of variants for diagnostic purposes.
The failure of pyrosequencing to adequately cover certain
amplicons may necessitate that standard sequencing be
performed on those DNA regions. However, as suggested
earlier, in diagnostic laboratories that routinely sequence
a defined set of amplicons, countermeasures can be
adopted to improve the coverage of amplicons.
Conclusion
This study confirms the high potential of massively paral-
lel pyrosequencing in the scanning of DNA samples for
sequence variations. Compared to traditional sequencing
technology, this system is capable of higher throughput
and is able to rapidly collect genomic information. Our
study highlighted some critical aspects of the technology
related to the uniformity of coverage. Based on our obser-
vation that the allelic fraction of variants approaches 0.5
as sequence coverage increases from 30× to over 2000×, in
future work coverage depth should be carefully consid-
ered, in particular for diagnostic applications; this is a fun-
damental issue for the reliable detection of heterozygous
variants. Moreover, since most sequencing errors were due
to indels in homopolymeric tracts, analytical approaches
might be specifically developed to better assess these var-
iants. Our results encourage future studies evaluating the
diagnostic applications of this sequencing technology in
diseases with high allelic and genetic heterogeneity.
Methods
DNA samples
We selected 16 human genes associated with human
genetic diseases (Table 1) and obtained corresponding
PCR-amplified material from the clinical inventory of San
Raffaele Hospital. A total of 343 amplicons were
obtained, representing 429 genetic variations already
identified by Sanger sequencing. DNA samples had been
obtained from patients who had given informed consent
or under protocols approved by the hospital's ethics
review board.
For all amplicons in the study, PCR had been performed
as previously described [14-22] or according to standard
procedures (indicated by an asterisk in Table 1). Ampli-
fied regions comprised entire exons with intron-exon
junctions or exon portions. Amplicons were checked for
quality on agarose gel electrophoresis and directly quanti-
fied after ethidium bromide staining using a gel scanner
(Typhoon 8600, Amersham).BMC Genomics 2008, 9:464 http://www.biomedcentral.com/1471-2164/9/464
Page 7 of 8
(page number not for citation purposes)
Amplicon pools
Amplicons were pooled into 4 samples in equimolar con-
centrations (Supplementary Table 1 [see Additional file
2]). On several occasions, one amplicon was included in
two or more pools. PCR products bearing the same varia-
tion were from different individuals, in order to increase
the variability under investigation.
Pools were purified using silica spin-columns (MinElute
PCR purification kit, Qiagen, Valencia, CA). Each pool
contained 2 μg DNA determined spectrophotometrically
(NanoDrop Technologies, Wilmington, Delaware USA).
The pools were checked for quality by capillary electro-
phoresis (Agilent Bioanalyzer 2100 with the DNA 1000
kit; Agilent Technologies, Palo Alto, CA, USA).
GS-FLX pyrosequencing
Pools were prepared for FLX sequencing following the
Low Molecular Weight DNA protocol as reported in the
454 Roche GS-FLX DNA Library Preparation Kit User
Manual. Each pool was separately loaded onto one-fourth
of a sequencing plate. Sequencing was performed accord-
ing to the manufacturer's instructions.
Sequence data analysis
GS-FLX reads were mapped to reference sequences using
Blast v. 2.2.15 [23], with e value set to 1e-7; low complex-
ity filter (DUST) disabled; word size, 4; and -v and -b set
to the highest possible number of matches (in a dataset
containing 100 000 reads, -v and -b are set to 100 000 or
higher). Other parameters were left at default. References
sequences were those of the NCBI human genome, build
36.3. The Blast output was stored in a PostgreSQL data-
base together with the corresponding read and reference.
Using each reference to collect its corresponding read set
from the database, the resulting multiple alignment was
used to calculate the percentage base call for every
sequence position with a coverage depth of 30 (or 10),
using a standard query language (SQL) query (available
upon request). We defined a sequence variation when
unexpected calls (with respect to the reference sequence)
exceeded a 20% allelic fraction (allelic fraction = mutated
allele counts/(wildtype allele counts + mutated allele
counts)) in regions having 30× (or 10×) depth coverage.
The detailed bioinformatics procedure will be published
separately.
Since preliminary work revealed that this Blast procedure
was inefficient on deletions and insertions larger than 10
bp, we further processed Blast outputs for reads that did
not uniquely match to the reference genome, searching
for those matching a single reference (amplicon)
sequence twice with proper strandedness.
Sequence variants were automatically classified by an SQL
query (available upon request) as follows:
- Top confident (TC): variation called by both forward and
reverse reads;
- Very confident (VC): variation called in consensus
regions where reads were available from one of the two
strands only;
- Not confident (NC): conflicting calls between forward
and reverse strands.
To visualize the sequence variants, the SeqMan package
(DNASTAR, Madison, WI, USA) was used.
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